| A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1) (NCT05487170) | Ranok Therapeutics (Hangzhou) Co., Ltd. | 2022-07-12 |
| Study of Orelabrutinib in Combination With Gemox in Refractory / Relapsed Diffuse Large B-cell Lymphoma (NCT05381506) | Sun Yat-sen University | 2022-07-01 |
| Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL (NCT05233033) | Kymera Therapeutics, Inc. | 2022-06-13 |
| Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL (NCT05093140) | Sun Yat-sen University | 2022-06-01 |
| Multiparametric Cardiac MRI in Patients Under CAR T-cell Therapy (NCT05414162) | University Hospital, Bonn | 2022-05-16 |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL (NCT05176691) | Hutchmed | 2022-02-15 |
| A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003) (NCT05139017) | Merck Sharp & Dohme LLC | 2022-01-14 |
| Study of Tafasitamab and Lenalinomide Associated to Rituximab in Frontline Diffuse Large B-Cell Lymphoma Patients of 80 y/o or Older (NCT04974216) | The Lymphoma Academic Research Organisation | 2021-12-20 |
| Ibrutinib Combined With Rituximab for Treatment of Relapsed Refractory MYD88 and CD79A/B (or CD79B Alone) DLBCL Who Have Received at Least Two Prior Therapies (NCT04994626) | Chinese Academy of Medical Sciences | 2021-10-01 |
| Efficacy and Safety of IBI110 Single Agent and in Combination With Sintilimab in Patients With Relapsed or Refractory Diffuse Large B Cell Lymphoma (r/r DLBCL) (NCT05039658) | Innovent Biologics (Suzhou) Co. Ltd. | 2021-09-27 |
| A Study of Polatuzumab Vedotin, Rituximab and Dose Attenuated CHP in Older Patients With DLBCL (NCT04594798) | University of Rochester | 2021-09-20 |
| Evaluate the Safety and Efficacy of Tafasitamab Combined With Lenalidomide in Patients With Relapsed or Refractory DLBCL (NCT05552937) | Beijing InnoCare Pharma Tech Co., Ltd. | 2021-09-06 |
| Ph I/II Study of E7777 Prior to CAR-T for R/R LBCL (NCT04855253) | Masonic Cancer Center, University of Minnesota | 2021-06-09 |
| Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia (NCT04806035) | TG Therapeutics, Inc. | 2021-04-28 |
| R2-CHOP in Untreated DEL-DLBCL：An Open-lable，Multicenter，Phase II Study (NCT04842487) | Sun Yat-sen University | 2021-04-10 |
| Split-Dose R-CHOP for Older Adults With DLBCL (NCT03943901) | University of Wisconsin, Madison | 2021-02-17 |
| Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma (NCT04512716) | Memorial Sloan Kettering Cancer Center | 2021-02-02 |
| Diet, Physical Activity and Body Composition Changes During R-CHOP (NCT04293900) | George Washington University | 2021-01-01 |
| A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies (NCT04072458) | Bio-Path Holdings, Inc. | 2020-11-05 |
| A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma (NCT04332822) | Nordic Lymphoma Group | 2020-08-19 |
| Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement (NCT04432714) | The First Affiliated Hospital with Nanjing Medical University | 2020-06-09 |
| Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma (NCT07041827) | The Netherlands Cancer Institute | 2020-02-01 |
| A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors (NCT03997968) | Cyteir Therapeutics, Inc. | 2019-10-09 |
| A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity (NCT03954106) | Jazz Pharmaceuticals | 2019-10-04 |
| A Study of Imvotamab Monotherapy and in Combination in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma (NCT04082936) | IGM Biosciences, Inc. | 2019-09-30 |
| Autologous CD22 CAR T Cells in Adults w/ Recurrent or Refractory B Cell Malignancies (NCT04088890) | Matthew Frank | 2019-09-12 |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma (NCT04002947) | National Cancer Institute (NCI) | 2019-08-05 |
| Ibrutinib + R-CHOP Followed by Ibrutinib Maintenance (NCT03731234) | Fondazione Italiana Linfomi - ETS | 2019-07-02 |
| A Study of PET Adapted Therapy and Non-invasive Monitoring for Previously Untreated Limited Stage Diffuse Large B Cell Lymphoma (NCT03758989) | University of Rochester | 2019-05-08 |
| The Feasibility and Clinical Efficacy of Atezolizumab Consolidation Treatment in High Risk (IPI > 2) DLBCL (NCT03463057) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2018-08-30 |
| Long-term Follow-up of Patients Treated With Genetically Modified Autologous T Cells (NCT03628612) | Autolus Limited | 2018-08-02 |
| Dose Dense Chemotherapy in Elderly Patients > 80 Years Old With DLBCL (NCT06150053) | University Hospital, Saarland | 2018-07-01 |
| Platform Study for the Treatment of Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma (PRISM Study) (NCT03527147) | Acerta Pharma BV | 2018-06-19 |
| Phase I-II Study in CD30 Positive Diffuse Large B-cell Lymphoma Patients Refractory to First Line Chemotherapy or in First Relapse (NCT03356054) | Stichting Hemato-Oncologie voor Volwassenen Nederland | 2018-03-05 |
| SMOLY : Phenotype and Functions of Monocyte Subtypes in High Grade B Lymphoma: Towards New Biomarkers? (NCT03672682) | Rennes University Hospital | 2017-09-01 |
| Study of Entospletinib (ENTO) in Newly Diagnosed DLBCL Patients With aaIPI>=1 Treated by Chemiotherapy (NCT03225924) | The Lymphoma Academic Research Organisation | 2017-07-26 |
| High-dose Intravenous Methotrexate Versus Intrathecal Methotrexate for Central Nervous System Prophylaxis in DLBCL (NCT03123718) | Chonnam National University Hospital | 2017-07-01 |
| Peptide Receptor Radionuclide Therapy With 90Y-Dotatoc in Relapsed/Refractory Diffuse Large B Cell and Mantle Cell Lymphomas (NCT02488512) | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS | 2016-12-22 |
| A Dose Exploration Study With Birabresib (MK-8628) in Participants With Selected Hematologic Malignancies (MK-8628-005) (NCT02698189) | Merck Sharp & Dohme LLC | 2016-05-19 |
| A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma (NCT02702141) | Seagen Inc. | 2016-02-01 |
| Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers (NCT01563302) | Ionis Pharmaceuticals, Inc. | 2012-02-27 |
| Assessment of Blood Biomarkers by DNA Microarrays in Patients With Aggressive Lymphoma BMS_LyTrans (NCT01287923) | Rennes University Hospital | 2011-02-21 |
| Evaluate a Treatment Adapted to the PET Response Compared to a Standard Treatment, for Low Risk DLBCL CD 20+ Patients (NCT01285765) | The Lymphoma Academic Research Organisation | 2010-12-01 |
| A Double-blind, Randomized Controlled Study in CD20-positive Diffuse B Cell Non-Hodgkin's Lymphoma Subjects (NCT01205737) | Teva Branded Pharmaceutical Products R&D, Inc. | 2010-09-01 |
| Expanded Access Program for Tafasitamab (MOR00208) in R/R DLBCL (NCT04300803) | MorphoSys AG | |